NOW RECRUITING PATIENTS! Updated March 20, 2019

Apellis Pharmacueuticals, Inc.

A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (DERBY)

Hoffmann-La Roche

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Diabetic Macular Edema (YOSEMITE)

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Diabetic Macular Edema (RHINE)

A Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) (ARCHWAY)

Chengdu Kanghong Biotech Co., Ltd.

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (PANDA-2)

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)

Please call 516-466-0390 if you are interested in participating in any of our actively recruiting trials.

2018-Current

Samsung Bioepis Co. Ltd

A Phase III Randomized, Double-Masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, Immunogenicity between SB11 (proposed ranibizuamb biosimilar) and Lucentis in subjects with Neovascular Age-related Macular Degeneration

2016-2017

Genentech/Roche
Stairway: Simultaneous Blockage of Angiopoientin-2 VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

2016-Present

Regeneron
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal REGEN910-3 in Patients with Neovascular Age-Related Macular Degeneration

2016-Present

Regeneron
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal REGEN910-3 in Patients with Diabetic Macular Edema

2016-Present

OHR Pharmaceuticals
OHR1601: A Phase III Study of the Effiacay and Saftey of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration

2015-Present

Genentech, Inc.
A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double- Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age Related Macular Degeneration

2015-Present

Allergan Pharmaceuticals
Safety and Efficacy of Abicipar Pegol(AGN-150998) in Patients with Neovascular Age-Related Degeneration

2015-2017

Regeneron Pharmaceuticals, Inc.
A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen- Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration

2014-Present

Genentech, Inc.
A Phase III, Multicenter, Randomized, Double-Masked, Sham-controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration